Pirfenidone treatment in XXXX : A Saudi experience.

@entity1 @entity2416
BACKGROUND: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of @entity2416 ( @entity2416 ). OBJECTIVE: To report on the efficacy and safety of pirfenidone in the treatment of @entity1 with @entity2416 , at a tertiary care hospital in Saudi Arabia. METHODS: The study included 58 @entity1 with @entity2416 who were evaluated from March 2012 to March 2013. During the study period, 33 @entity1 received pirfenidone, and the remaining @entity1 (n = 25) served as a control group. Baseline clinical characteristics, physiological parameters and the results of a 36-Item Short Form Health Survey (SF-36) were compared between the groups. Furthermore, we compared changes in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLco), six-minute walk distance (6MWD) and SF-36 for both groups during follow-up. The last follow-up period ended in January 2014. RESULTS: There were no significant differences in baseline clinical characteristics between the groups. Furthermore, we found no differences in FVC, DLco and SF-36 during follow-up (median, 12 months). However, @entity1 receiving pirfenidone treatment were less likely to experience reductions in 6MWD compared with the control group (13% vs. 52%, respectively; P = 0.001). Although adverse events were more frequently reported by the pirfenidone group compared with the control group (85 vs. 56%, respectively; P = 0.015), these @entity1 did not require discontinuation of treatment. CONCLUSION: Pirfenidone treatment preserves functional capacity, as reflected by the 6MWD. Adverse events associated with pirfenidone treatment were generally well tolerated by the @entity1 .
